Preventing whisker growth from an L-menthol composition
A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.
1. A method comprising preventing whisker growth from an L-menthol pharmaceutical dosage form capsule, tablet, or sachet composition by:
forming a solid core of the pharmaceutical dosage form, the solid core including solid L-menthol;
coating the solid core with a proteinaceous material that substantially prevents the solid L-menthol from forming whiskers when the core is stored at a temperature of 40 degrees C. and 75% relative humidity for 30 days; and
drying the proteinaceous material over the solid core to form a proteinaceous material coated core;
wherein the pharmaceutical dosage form is a multiparticulate dosage form including a plurality of the cores, the plurality of cores being spheroidal and having a diameter of 0.1 to 3 mm.
2. The method of claim 1 , wherein coating the solid core with a proteinaceous material is achieved by spraying the proteinaceous material over the solid core.
3. The method of claim 1 , further comprising, micronizing the L-menthol crystals by jet milling.
4. The method of claim 1 , wherein coating the solid core with a proteinaceous material includes spraying a solution containing about 5% to about 30% gelatin over the proteinaceous material coated core.
5. The method of claim 1 , wherein coating the solid core with a proteinaceous material includes spraying a solution containing at least about 50% gelatin over the proteinaceous material coated core.
6. The method of claim 1 , wherein the proteinaceous material includes acid bone gelatin.
7. The method of claim 1 , further comprising applying an enteric coating over the proteinaceous material coated core.
8. The method of claim 1 , wherein the proteinaceous material includes an aqueous solution of acid bone gelatin.
9. The method of claim 1 , wherein the proteinaceous material is an aqueous gelatin solution and the method further comprises micronizing the solid L-menthol by jet milling.
10. The method of claim 1 , wherein the pharmaceutical dosage form is a multiparticulate dosage form including a plurality of the cores, the plurality of cores being spheroidal and having a diameter of 0.1 to 3 mm; the proteinaceous material is an aqueous gelatin solution; and the method further comprises micronizing the solid L-menthol by jet milling.
11. The method of claim 1 , further comprising coating the proteinaceous material coated cores with a coating that substantially prevents the L-menthol from releasing into the stomach and allows the L-menthol to release in the intestines.